

Respiratory Syncytial Virus (RSV) Enrollment Form 2016-2017

Date Needed _____ Please complete this form and fax to 866.823.9681

1. PATIENT INFORMATION (Please print or type clearly)	CLINICAL INFORMATION & MEDICAL ASSESSMENT (CONT'D)
NameToday's Date	
Street Address	 Patient is 12 months of age or younger with hemodynamically significant congenital heart disease ☐ Yes* ☐ No
City State Zip Code	Patient has the following condition(s): ☐ Diagnosis of moderate-severe pulmonary hypertension ICD-10: ☐ Cyanotic heart disease (in consultation with a pediatric cardiologist) ICD-10:
Phone Numbers (Include Area Code): Day	
Night Cell Phone	
Date of Birth	□ Acyanotic heart disease (receiving medication to control CHF & will require cardiac surgical procedures) – ICD-10:
Allergies	☐ Medications to control CHF:
Primary Caregiver Phone	Last date received:
Emergency Contact Phone	4. Patient is younger than 24 months of age and has undergone
INSURANCE INFORMATION (Include copies of insurance card - front and back): Primary Insurance Phone	cardiac transplantation during the RSV season.
Name of Cardholder	5. Neuromuscular Disease/Congenital Airway Abnormality with impaired ability to
ID # Group #	clear secretions from upper airway during first year of life: ☐ Yes* ☐ No☐ Severe neuromuscular disease ICD-10:
DELIVERY INSTRUCTIONS:	☐ Congenital or other pulmonary abnormality ICD-10:
□ Physician □ Other	Profoundly immunocompromised or receiving chemotherapy during RSV
Address City State	season and younger than 24 months of age.
2. PRESCRIBER INFORMATION *Indicates Required Field	7. Patient has a diagnosis of Cystic Fibrosis as well as:
Prescriber First and Last Name*	 ☐ Clinical evidence of CLD (under 12 months of age)* ☐ Nutritional compromise (under 12 months of age)*
NPI #*DEA #	☐ Manifestations of severe lung disease (12-24 months of age)*
Facility Name	(Previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities
Street Address*	on chest radiography or chest computed tomography that persist when stable.)
City* State* Zip Code*	☐ Weight for length less than 10 th percentile (12-24 months of age)*
Phone #* Fax #	4. NICU HISTORY:
Form Submitted By	Did the patient spend time in the NICU? ☐ Yes ☐ No
CONTACT:	If yes, please attach the NICU Discharge Summary Was there a NICU/HOSPITAL RSV dose administered?
Healthcare Professional Phone #	☐ Yes - Date(s): ☐ No
3. CLINICAL INFORMATION & MEDICAL ASSESSMENT	Agency nurse to visit home for injection? Yes No Agency Name:
Patient's Gestational Age: weeks days Birth Weight g/kg/lbs	*PLEASE PROVIDE CLINICAL DOCUMENTATION WHERE REQUESTED
Current Weight g/kg/lbs Date Recorded:	
Please document all diagnoses and provide the specific ICD-10 code for each.	
1. Prematurity: Infants younger than 12 months of age at the start of RSV season and who were born at or before 28 weeks, 6 days gestation	RX □ Synagis® (palivizumab): Combination of 50- and/or 100-mg vials
ICD-10 (P07.21 through P07.31, please indicate): 2. Diagnosis of chronic lung disease (CLD) and younger than 12 months of age?	Sig: Inject 15 mg/kg IM one time per month Dispense Quantity: QS Refill xmonths (required)
Yes* No ICD-10: Yes No Gestational Age ≤ 31 weeks, 6 days ICD-10:	
☐ Yes* ☐ No Patient required >21% oxygen for at least the first 28 days after birth	Other:
☐ Yes* ☐ No Patient is 12 to 24 months of age, meets all CLD requirements	EXPECTED DATE OF FIRST/NEXT INJECTION: Previous injection(s) given? □ Yes □ No
above and continues to require medical support for CLD within 6 months of the start of RSV season (check all that apply and provide last date received):	Please list all previous injection dates:
Oxygen (Date): Corticosteroids (Date):	
☐ Diuretics (Date):	
Prescriber's Signature	Date

I authorize Amber Pharmacy and its representatives to act as my agent to initiate and execute the insurance prior authorization process and, in doing so, to release clinical information via phone or fax to the appropriate PBM.

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, and proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. 082212